Literature DB >> 29306837

Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.

A Prasanth Saraswati1, S M Ali Hussaini2, Namballa Hari Krishna3, Bathini Nagendra Babu1, Ahmed Kamal4.   

Abstract

Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase which is ubiquitously expressed and is regarded as a regulator for various cellular events and signalling pathways. It exists in two isoforms, GSK-3α and GSK-3β and can phosphorylate a wide range of substrates. Aberrancy in the GSK-3 activity can lead to various diseases like Alzheimer's, diabetes, cancer, neurodegeneration etc., rendering it an attractive target to develop potent and specific inhibitors. The present review focuses on the recent developments in the area of GSK-3 inhibitors and also enlightens its therapeutic applicability in various disease conditions.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer's; Cancer; Diabetes; GSK-3 inhibitors; Neurodegeneration

Mesh:

Substances:

Year:  2017        PMID: 29306837     DOI: 10.1016/j.ejmech.2017.11.103

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  32 in total

1.  Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3.

Authors:  Mahboubeh S Noori; Pooja M Bhatt; Maria C Courreges; Davoud Ghazanfari; Chaz Cuckler; Crina M Orac; Mark C McMills; Frank L Schwartz; Sudhir P Deosarkar; Stephen C Bergmeier; Kelly D McCall; Douglas J Goetz
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

2.  The pivotal role of glycogen synthase kinase 3 (GSK-3) in vomiting evoked by specific emetogens in the least shrew (Cryptotis parva).

Authors:  W Zhong; N A Darmani
Journal:  Neurochem Int       Date:  2019-11-15       Impact factor: 3.921

3.  Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand.

Authors:  Jaya Prabhakaran; Kiran Kumar Solingapuram Sai; Anirudh Sattiraju; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2019-01-25       Impact factor: 2.823

4.  GSK3β inhibits epithelial-mesenchymal transition via the Wnt/β-catenin and PI3K/Akt pathways.

Authors:  Cheng Zhang; Li Su; Li Huang; Zheng-Yu Song
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

5.  Perspectives on the Clinical Development of NRF2-Targeting Drugs.

Authors:  Diego Lastra; Raquel Fernández-Ginés; Gina Manda; Antonio Cuadrado
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor.

Authors:  Sean D Allen; Xiangsheng Liu; Jinhong Jiang; Yu-Pei Liao; Chong Hyun Chang; Andre E Nel; Huan Meng
Journal:  Biomaterials       Date:  2020-12-28       Impact factor: 12.479

Review 7.  Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.

Authors:  William D Hedrich; Hongbing Wang
Journal:  Pharm Res       Date:  2021-02-22       Impact factor: 4.200

8.  Glycogen synthase kinase 3 beta inhibitor SB216763 improves Kir2.1 expression after myocardia infraction in rats.

Authors:  Cheng Chang; Shu-Hui Wang; Li-Na Xu; Xue-Ling Su; Yi-Fan Zeng; Peng Wang; Li-Rong Zhang; Sheng-Na Han
Journal:  J Interv Card Electrophysiol       Date:  2021-02-20       Impact factor: 1.900

Review 9.  Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems.

Authors:  Weixia Zhong; Omar Shahbaz; Garrett Teskey; Abrianna Beever; Nala Kachour; Vishwanath Venketaraman; Nissar A Darmani
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.

Authors:  Hemn Mohammadpour; Joseph L Sarow; Cameron R MacDonald; George L Chen; Jingxin Qiu; Umesh C Sharma; Xuefang Cao; Megan M Herr; Theresa E Hahn; Bruce R Blazar; Elizabeth A Repasky; Philip L McCarthy
Journal:  JCI Insight       Date:  2020-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.